Horse Chestnut: Aescin and How It Works

Table of Contents

1. What Aescin Is
2. The Leaky-Vessel Problem It Is Meant to Address
3. Three Proposed Actions: Anti-Oedema, Anti-Inflammatory, Venotonic
4. The Molecular Explanations on Offer
5. What Has Been Measured in People
6. Absorption and Metabolism
7. Injected Aescin Is a Different Drug
8. Cancer and Other Laboratory Research
9. Aescin in Stockings and Gels
10. Mechanism Evidence by Tier
11. Key Research Papers
12. Connections

What Aescin Is

Aescin is not a single molecule. It is a mixture of closely related triterpenoid saponins. A saponin is a molecule with a fat-loving, ring-shaped core and one or more water-loving sugar chains attached; the combination makes saponins behave a little like soap, and many of them foam in water. In aescin the core is a five-ring (pentacyclic) triterpene of the oleanane type, which is how a 2023 review describes β-escin.

The EMA report describes three fractions in the older literature: crypto-aescin, β-aescin and α-aescin (a mixture of the first two). They differ in where an acetyl group sits on the molecule. That small chemical difference has a real consequence: according to the EMA report, β-aescin has haemolytic activity — it can break open red blood cells in laboratory tests — while crypto-aescin does not.

Sirtori's 2001 review calls aescin the major active principle of the horse chestnut tree. Other reviews describe it simply as "the active component" of the seed. The seed also contains flavonoids, sterols and a great deal of starch (30–60% according to the EMA), and the extracts used in trials were standardised on aescin content, not purified to aescin alone.

Back to Table of Contents

The Leaky-Vessel Problem It Is Meant to Address

To see why aescin attracted interest, it helps to know where leg swelling comes from. In chronic venous insufficiency, high pressure in the leg veins pushes back into the tiniest blood vessels, the capillaries. Their walls are lined by a single layer of endothelial cells. Under pressure and inflammation the gaps between those cells widen, fluid and proteins leak into the surrounding tissue, and the result is oedema — swelling. White blood cells also stick to the walls of the strained veins and valves and release inflammatory signals, which is thought to damage the valves further over time.

A 2025 review of the whole class of venoactive drugs describes their shared proposed effects in exactly these terms: sealing the endothelial barrier, improving lymphatic drainage, reducing oedema, improving venous tone, inhibiting white-cell adhesion to vein walls and valves and the release of inflammatory mediators, lowering blood viscosity, and making red blood cells more flexible. Aescin is one of the compounds that review covers.

Back to Table of Contents

Three Proposed Actions: Anti-Oedema, Anti-Inflammatory, Venotonic

Reviews group aescin's proposed effects under three headings:

Anti-oedematous: less leakage

Gallelli's 2019 review reports that more recent data confirm aescin reduces vascular permeability in inflamed tissue, thereby inhibiting the formation of oedema. The EMA report summarises older animal experiments, for example significantly reduced swelling after egg-albumin injection into the rat paw (a standard laboratory model of inflammatory swelling) when aescin was given intravenously.

Anti-inflammatory

Aescin's anti-inflammatory effects "have been studied over many years in pre-clinical models", in Gallelli's words. A 2025 review of saponins from medicinal plants places escin alongside ginsenosides, glycyrrhizin, astragaloside and saikosaponins as anti-inflammatory saponins acting through multiple pathways in experimental systems.

Venotonic: firmer vein walls

"Venotonic" means increasing the tone, or tension, of the vein wall, so a vein holds less pooled blood. Gallelli states that aescin's venotonic effects "have been demonstrated primarily by in vitro studies of isolated human saphenous veins" — strips of leg vein removed during surgery and tested in an organ bath. Sirtori's review describes improved entry of ions into channels, raising venous tension in both laboratory and animal conditions.

Back to Table of Contents

The Molecular Explanations on Offer

Several molecular explanations have been proposed. None is settled, and they are not mutually exclusive.

• Prostaglandin and receptor effects. Sirtori's review lists the release of the prostaglandin PGF2α from veins (which contracts vein muscle), antagonism to serotonin (5-HT) and histamine (two inflammatory signals that make vessels leaky), and reduced breakdown of tissue mucopolysaccharides (the gel-like material between cells).
• Protecting the endothelial junction. Gallelli's review reports that aescin prevents hypoxia-induced disruption to the normal expression and distribution of PECAM-1, a protein that helps hold endothelial cells together, which "may help explain" its protective effect on vessel permeability. Hypoxia (low oxygen) is what happens in pooled venous blood.
• Signalling pathways. A 2023 review lists a long series of signalling pathways and proteins that β-escin influences in laboratory studies, including PI3K/Akt, RhoA/ROCK, TNF-α and matrix metalloproteinases.
• Ion channels. A 2024 review lists escin among natural compounds that inhibit Piezo1, a channel in cell membranes that opens in response to mechanical pressure and lets calcium into cells. Because veins in CVI are under mechanical strain, this is an intriguing laboratory link, but the review frames Piezo1 inhibitors as at an early stage of development.

Back to Table of Contents

What Has Been Measured in People

A small number of measurements in people sit between the laboratory and the trials. The EMA report describes a double-blind crossover study (Bisler, 1986) in 22 women with chronic venous insufficiency: three hours after a single dose of extract providing 100 mg aescin, the capillary filtration coefficient — a measure of how fast fluid leaves the small vessels of the lower leg — had fallen by 22%, compared with a slight rise on placebo. Older studies in healthy volunteers from the 1950s and 1960s reported lower capillary filtration and a dose-dependent increase in vein tone two hours after single oral doses; in one of them, 20 mg of aescin given intravenously had no effect on vein tone. The EMA concludes that the exact mechanism of action "is not known", but that preclinical and clinical pharmacology studies indicate an effect on venous tone and capillary filtration rate is involved.

That is the honest summary: a plausible mechanism with some direct human measurements, resting mostly on animal and isolated-tissue work, standing behind a modest but consistent clinical effect on leg swelling. The clinical evidence is on the page Chronic Venous Insufficiency Evidence.

Back to Table of Contents

Absorption and Metabolism

The 2023 review of β-escin reports that it is more than 90% bound to plasma proteins, that it is metabolised mainly by the liver and kidneys and excreted in urine and faeces, and that gut-bacteria enzymes can convert it into several derivatives. The same review describes the published data on its metabolism as relatively small in number and "vague".

The EMA report is similarly cautious. Because of uncertainty in the analytical data, it declined to give precise pharmacokinetic figures in the monograph, but concluded that there is virtually no difference in aescin bioavailability between slow-release and immediate-release preparations.

Back to Table of Contents

Injected Aescin Is a Different Drug

Aescin is not only an oral herbal product. Sodium aescinate (sodium β-aescin) is given by injection in some countries. A 2008 paper reports that it is approved under China's national drug standard and is used clinically for brain swelling and for swelling caused by trauma or surgery. That paper went on to propose sodium β-aescin as a possible treatment for Bell's palsy (a sudden facial paralysis thought to involve swelling of the facial nerve), but it was a hypothesis paper, not a trial; it presented no patient data.

Injection changes the safety picture. The EMA report records that a concern about acute kidney failure arose decades ago when heart-surgery patients were given high intravenous doses, and that three follow-up clinical studies of injected aescin in 83 people found no kidney impairment at the doses tested. A 2016 study in zebrafish larvae found that sodium aescinate injected into the yolk sac caused heart malformations and slowed heart rate and circulation at the doses tested. Zebrafish larvae are a screening model; the authors called for more attention to the risk in clinical use, and the finding has not been shown in people.

Back to Table of Contents

Cancer and Other Laboratory Research

Aescin is biologically active enough to have generated a large laboratory literature far from leg veins:

• Cancer cells. A 2018 review reports that escin slows growth and induces cell death in many cancer cell models, including lung adenocarcinoma, liver cancer and leukaemia; reduces tumour growth and spread in various animal models; and enhances the effects of some chemotherapy drugs in those models. The review describes this as an area of active investigation.
• Cytotoxicity. The 2023 review describes β-escin as having "significant cytotoxicity", and reports work on chemically packaging it to reduce toxicity.
• Lung fibrosis. A 2025 study found that escin raised levels of nephronectin, a protein the authors identified as protective against cellular ageing, and alleviated experimentally induced pulmonary fibrosis in mice.

None of these findings comes from people. The step from cell culture or a mouse model to a safe, effective human treatment is a long one, and the same 2023 review that lists these activities also describes β-escin as significantly cytotoxic. No human cancer trial of aescin is described in the records reviewed for this page.

Back to Table of Contents

Aescin in Stockings and Gels

Because aescin is meant to act on skin and vessels, researchers have tried to deliver it locally. Gallelli's review describes an aescin gel applied to the skin (transdermal) alongside the oral tablets, with efficacy reported in blunt injuries and chronic venous insufficiency. A 2017 chemistry study went further, examining how aescin fits inside cyclodextrins — ring-shaped sugar molecules used as molecular containers — as a way of incorporating it into the fabric of stockings. The study found that the larger γ-cyclodextrin is the most suitable host. It is a materials-science paper; it did not test any garment on people.

The topical side of horse chestnut is covered on Haemorrhoids, Bruising and Topical Use.

Back to Table of Contents

Mechanism Evidence by Tier

• Human trials (clinical outcome): reduced leg volume and leg pain in chronic venous insufficiency with the standardised seed extract. Modest, consistent, short-term.
• Human pharmacology: reduced capillary filtration and changes in vein tone after single doses, per the EMA report.
• Isolated human tissue: venotonic effects on human saphenous vein strips.
• Animal studies: anti-oedema and anti-inflammatory effects in rodent models; reduced lung fibrosis in mice; tumour effects in animal models.
• Cell culture and chemistry: endothelial junction protection, signalling-pathway effects, Piezo1 inhibition, cancer-cell killing, cyclodextrin packaging.

The further down this list a claim sits, the less it says about what an oral supplement does in a person.

Back to Table of Contents

Key Research Papers

1. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacological research. 2001;44(3):183-93. PubMed PMID: 11529685
2. Gallelli L. Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug design, development and therapy. 2019;13():3425-3437. PubMed PMID: 31631970
3. Wang Y, Han X, Wan X, et al.. β-Escin: An Updated Review of Its Analysis, Pharmacology, Pharmacokinetics, and Toxicity. The American journal of Chinese medicine. 2023;51(8):2095-2120. PubMed PMID: 37865870
4. Gloviczki ML, Kakkos SK, Urbanek T, et al.. The role of venoactive compounds in the treatment of chronic venous disease. Journal of vascular surgery. Venous and lymphatic disorders. 2025;13(5):102258. PubMed PMID: 40348378
5. Zheng Q, Wang T, Wang S, et al.. The anti-inflammatory effects of saponins from natural herbs. Pharmacology & therapeutics. 2025;269():108827. PubMed PMID: 40015518
6. Thien ND, Hai-Nam N, Anh DT, et al.. Piezo1 and its inhibitors: Overview and perspectives. European journal of medicinal chemistry. 2024;273():116502. PubMed PMID: 38761789
7. Cheong DHJ, Arfuso F, Sethi G, et al.. Molecular targets and anti-cancer potential of escin. Cancer letters. 2018;422():1-8. PubMed PMID: 29474858
8. Guo J, Wang Y, Liu Q, et al.. Nephronectin (NPNT) is a Crucial Determinant of Idiopathic Pulmonary Fibrosis: Modulating Cellular Senescence via the ITGA3/YAP1 Signaling Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025;12(32):e01956. PubMed PMID: 40444575
9. Liu J, Li Y, Yuan X, et al.. Sodium beta-aescin may be an effective therapeutic agent for Bell's palsy. Medical hypotheses. 2008;71(5):762-4. PubMed PMID: 18762387
10. Liang J, Jin W, Li H, et al.. In Vivo Cardiotoxicity Induced by Sodium Aescinate in Zebrafish Larvae. Molecules (Basel, Switzerland). 2016;21(3):190. PubMed PMID: 26907249
11. Ramos AI, Vaz PD, Braga SS, et al.. Association of aescin with β- and γ-cyclodextrins studied by DFT calculations and spectroscopic methods. Beilstein journal of nanotechnology. 2017;8():348-357. PubMed PMID: 28890859
12. Bencsik T, Balázs VL, Farkas Á, et al.. Herbal drugs in chronic venous disease treatment: An update. Fitoterapia. 2024;179():106256. PubMed PMID: 39419127
13. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. 2012;11(11):CD003230. PubMed PMID: 23152216

PubMed Topic Searches

1. PubMed: escin and endothelial permeability
2. PubMed: aescin and venous tone
3. PubMed: β-escin pharmacokinetics

Back to Table of Contents

Connections

• Heart, Liver and Metabolic Herbs — the parent category
• Horse Chestnut (Aesculus hippocastanum) — the main page
• Horse Chestnut: Benefits Deep Dive — the hub
• Chronic Venous Insufficiency Evidence — the clinical trials
• Raw Seed Poisoning and Esculin — the raw plant
• Haemorrhoids, Bruising and Topical Use — gels and creams
• Quinoa: Saponin Removal — saponins in an everyday food
• Edema — why tissue swells
• Varicose Veins — the condition
• How Veins Return Blood (animation) — valves and the calf pump
• Rutin: Veins and Capillaries — a flavonoid with similar claims
• Hesperidin: Veins and Circulation — the flavonoid fraction
• Gotu Kola: Venous Insufficiency — another plant venoactive

Back to top